ArticleVirology journal2026
SARS-CoV-2 mRNA XBB1.5 vaccine immunogenicity in kidney transplant recipients.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDespite the reduced clinical severity of Omicron SARS-CoV-2 variants compared to earlier lineages, kidney transplant recipients (KTR) continue to experience higher SARS-CoV-2 mortality rates than the general population. Seroconversion rates following SARS-CoV-2 mRNA vaccination remain lower in KTR after three vaccine injections.
methodsWe evaluated anti-SARS-CoV-2 neutralizing antibody activity and cellular responses, as well as whole blood gene expression profiles after XBB.1.5 mRNA vaccination boost in a cohort of KTR.
resultsWe demonstrated that XBB.1.5 mRNA boosting increased both the magnitude and frequency of neutralizing antibody responses against different SARS-CoV-2 variants and found that the neutralizing activity against Wuhan strain or XBB.1.5 subvariant was driven by different anti-Spike binding IgG subclasses. We also demonstrated that Spike-specific CD4⁺ T-cell responses were significantly boosted against Wuhan strain and XBB.1.5 subvariant one month following XBB.1.5 mRNA vaccination. Lastly, we showed that XBB.1.5 boost induced overexpression of genes associated with type I IFN and innate immune responses at day 1, but also activated T and NK-cells at day 3 that persist at day 7 post-vaccination.
conclusionsGlobally, increasing the number of vaccine injections using updated XBB.1.5 mRNA vaccine enhance anti-SARS-CoV-2 immune responses in KTR. However, the monovalent XBB.1.5 mRNA vaccine boost elicited recall of cross-reacting immune responses against the original Wuhan Spike without a clear advantage against Omicron subvariants, consistent with a predominant immunological imprinting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.